Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

NCT02249130 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Tipranavir (TPV)
DRUG: Ritonavir (RTV)
DRUG: Delavirdine (DLV)
DRUG: Zidovudine (ZDV)
DRUG: Lamivudine (3TC)
DRUG: Stavudine (d4T)

Sponsor

Boehringer Ingelheim